Allakos Research Development vs Total Operating Expenses Analysis

ALLK Stock

USD 1.03 0.02 1.98%

Allakos financial indicator trend analysis is way more than just evaluating Allakos prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Allakos is a good investment. Please check the relationship between Allakos Research Development and its Total Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allakos. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Allakos Stock please use our How to buy in Allakos Stock guide.

Research Development vs Total Operating Expenses

Research Development vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Allakos Research Development account and Total Operating Expenses. At this time, the significance of the direction appears to have totally related.

The correlation between Allakos' Research Development and Total Operating Expenses is 1.0. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Allakos, assuming nothing else is changed. The correlation between historical values of Allakos' Research Development and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Allakos are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Research Development i.e., Allakos' Research Development and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most indicators from Allakos' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Allakos current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allakos. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Allakos Stock please use our How to buy in Allakos Stock guide.Enterprise Value is expected to rise to about 784.5 M this year, although the value of Tax Provision is projected to rise to (1.6 M).

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.3M	7.1M	6.1M	6.4M
Interest Income	377K	3.7M	10.7M	11.3M

Depreciation And Amortization Interest Income

Allakos fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.75	0.49	0.75	0.99	0.87	0.98	0.77	-0.76	-0.54	0.87	0.86	0.76	0.58	0.59	-0.19	0.99	0.7	0.53	-0.19	-0.27	0.78	0.74	0.82	0.09	0.71
Short Long Term Debt Total	0.75		0.84	0.95	0.71	0.85	0.77	0.98	-0.55	-0.84	0.68	0.78	0.98	0.93	0.85	-0.34	0.67	0.8	0.83	-0.34	-0.13	0.89	0.88	0.94	0.32	0.98
Other Current Liab	0.49	0.84		0.86	0.44	0.8	0.54	0.84	-0.2	-0.97	0.28	0.52	0.84	0.88	0.97	-0.74	0.4	0.88	0.85	-0.74	-0.09	0.9	0.68	0.81	0.36	0.87
Total Current Liabilities	0.75	0.95	0.86		0.71	0.89	0.79	0.98	-0.49	-0.87	0.65	0.71	0.98	0.96	0.91	-0.38	0.66	0.84	0.87	-0.38	-0.17	0.91	0.86	0.96	0.3	0.98
Total Stockholder Equity	0.99	0.71	0.44	0.71		0.86	0.98	0.73	-0.7	-0.51	0.85	0.8	0.72	0.54	0.56	-0.17	0.99	0.69	0.48	-0.17	-0.39	0.75	0.7	0.79	-0.05	0.67
Other Liab	0.87	0.85	0.8	0.89	0.86		0.91	0.87	-0.46	-0.86	0.6	0.69	0.87	0.79	0.88	-0.54	0.83	0.94	0.81	-0.54	-0.33	0.97	0.71	0.95	0.12	0.85
Net Tangible Assets	0.98	0.77	0.54	0.79	0.98	0.91		0.78	-0.67	-0.61	0.8	0.79	0.78	0.62	0.64	-0.26	0.96	0.77	0.62	-0.26	-0.4	0.83	0.68	0.87	-0.02	0.75
Property Plant And Equipment Net	0.77	0.98	0.84	0.98	0.73	0.87	0.78		-0.54	-0.85	0.68	0.76	1.0	0.96	0.88	-0.32	0.68	0.83	0.82	-0.32	-0.15	0.9	0.91	0.95	0.3	0.99
Net Debt	-0.76	-0.55	-0.2	-0.49	-0.7	-0.46	-0.67	-0.54		0.2	-0.87	-0.94	-0.52	-0.34	-0.22	-0.1	-0.76	-0.29	-0.24	-0.1	-0.24	-0.4	-0.61	-0.5	-0.44	-0.5
Retained Earnings	-0.54	-0.84	-0.97	-0.87	-0.51	-0.86	-0.61	-0.85	0.2		-0.26	-0.51	-0.85	-0.89	-0.97	0.72	-0.46	-0.95	-0.89	0.72	0.15	-0.95	-0.63	-0.87	-0.29	-0.88
Accounts Payable	0.87	0.68	0.28	0.65	0.85	0.6	0.8	0.68	-0.87	-0.26		0.87	0.67	0.47	0.35	0.16	0.86	0.36	0.33	0.16	-0.11	0.5	0.8	0.63	0.16	0.62
Cash	0.86	0.78	0.52	0.71	0.8	0.69	0.79	0.76	-0.94	-0.51	0.87		0.74	0.59	0.53	-0.18	0.83	0.56	0.48	-0.18	0.13	0.68	0.78	0.72	0.46	0.73
Non Current Assets Total	0.76	0.98	0.84	0.98	0.72	0.87	0.78	1.0	-0.52	-0.85	0.67	0.74		0.97	0.89	-0.32	0.67	0.83	0.82	-0.32	-0.15	0.9	0.91	0.95	0.3	0.99
Non Currrent Assets Other	0.58	0.93	0.88	0.96	0.54	0.79	0.62	0.96	-0.34	-0.89	0.47	0.59	0.97		0.91	-0.36	0.47	0.82	0.86	-0.36	-0.1	0.86	0.83	0.91	0.34	0.97
Other Assets	0.59	0.85	0.97	0.91	0.56	0.88	0.64	0.88	-0.22	-0.97	0.35	0.53	0.89	0.91		-0.67	0.5	0.92	0.86	-0.67	-0.17	0.94	0.73	0.87	0.29	0.89
Long Term Debt	-0.19	-0.34	-0.74	-0.38	-0.17	-0.54	-0.26	-0.32	-0.1	0.72	0.16	-0.18	-0.32	-0.36	-0.67		-0.16	-0.68	-0.5	1.0	0.11	-0.63	-0.13	-0.37	-0.16	-0.36
Cash And Short Term Investments	0.99	0.67	0.4	0.66	0.99	0.83	0.96	0.68	-0.76	-0.46	0.86	0.83	0.67	0.47	0.5	-0.16		0.64	0.45	-0.16	-0.28	0.72	0.66	0.75	0.04	0.62
Common Stock Total Equity	0.7	0.8	0.88	0.84	0.69	0.94	0.77	0.83	-0.29	-0.95	0.36	0.56	0.83	0.82	0.92	-0.68	0.64		0.81	-0.68	-0.33	0.98	0.61	0.89	0.11	0.84
Common Stock Shares Outstanding	0.53	0.83	0.85	0.87	0.48	0.81	0.62	0.82	-0.24	-0.89	0.33	0.48	0.82	0.86	0.86	-0.5	0.45	0.81		-0.5	-0.08	0.85	0.55	0.89	0.33	0.86
Long Term Debt Total	-0.19	-0.34	-0.74	-0.38	-0.17	-0.54	-0.26	-0.32	-0.1	0.72	0.16	-0.18	-0.32	-0.36	-0.67	1.0	-0.16	-0.68	-0.5		0.11	-0.63	-0.13	-0.37	-0.16	-0.36
Non Current Liabilities Total	-0.27	-0.13	-0.09	-0.17	-0.39	-0.33	-0.4	-0.15	-0.24	0.15	-0.11	0.13	-0.15	-0.1	-0.17	0.11	-0.28	-0.33	-0.08	0.11		-0.27	-0.07	-0.23	0.88	-0.14
Capital Surpluse	0.78	0.89	0.9	0.91	0.75	0.97	0.83	0.9	-0.4	-0.95	0.5	0.68	0.9	0.86	0.94	-0.63	0.72	0.98	0.85	-0.63	-0.27		0.72	0.95	0.2	0.9
Other Current Assets	0.74	0.88	0.68	0.86	0.7	0.71	0.68	0.91	-0.61	-0.63	0.8	0.78	0.91	0.83	0.73	-0.13	0.66	0.61	0.55	-0.13	-0.07	0.72		0.78	0.33	0.86
Other Stockholder Equity	0.82	0.94	0.81	0.96	0.79	0.95	0.87	0.95	-0.5	-0.87	0.63	0.72	0.95	0.91	0.87	-0.37	0.75	0.89	0.89	-0.37	-0.23	0.95	0.78		0.22	0.95
Total Liab	0.09	0.32	0.36	0.3	-0.05	0.12	-0.02	0.3	-0.44	-0.29	0.16	0.46	0.3	0.34	0.29	-0.16	0.04	0.11	0.33	-0.16	0.88	0.2	0.33	0.22		0.32
Property Plant And Equipment Gross	0.71	0.98	0.87	0.98	0.67	0.85	0.75	0.99	-0.5	-0.88	0.62	0.73	0.99	0.97	0.89	-0.36	0.62	0.84	0.86	-0.36	-0.14	0.9	0.86	0.95	0.32

Click cells to compare fundamentals

Allakos Account Relationship Matchups

Allakos fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	516.9M	719.6M	534.8M	386.4M	243.6M	370.4M
Short Long Term Debt Total	8.5M	42.8M	49.1M	49.1M	41.5M	30.8M
Other Current Liab	90K	8.0M	24.2M	22.0M	31.6M	33.1M
Total Current Liabilities	13.1M	22.5M	40.2M	30.0M	36.6M	21.0M
Total Stockholder Equity	495.7M	654.4M	445.5M	310.4M	168.8M	297.5M
Net Tangible Assets	495.7M	654.4M	445.5M	310.4M	357.0M	313.5M
Property Plant And Equipment Net	14.2M	48.1M	74.8M	69.4M	57.5M	37.6M
Net Debt	(29.8M)	(164.4M)	(103.7M)	(38.1M)	(25.0M)	(26.2M)
Retained Earnings	(189.5M)	(343.0M)	(612.8M)	(932.8M)	(1.1B)	(1.1B)
Accounts Payable	6.0M	14.0M	13.7M	4.8M	1.8M	1.7M
Cash	38.4M	207.2M	152.8M	87.2M	66.4M	94.1M
Non Current Assets Total	17.0M	50.4M	83.2M	77.6M	63.7M	41.7M
Non Currrent Assets Other	564K	2.3M	6.2M	6.7M	6.2M	3.2M
Other Assets	2.8M	2.3M	8.4M	8.2M	9.4M	9.9M
Cash And Short Term Investments	495.9M	659.0M	424.2M	279.8M	170.8M	317.2M
Common Stock Total Equity	48K	53K	54K	85K	97.8K	102.6K
Common Stock Shares Outstanding	45.2M	49.5M	53.8M	63.3M	86.8M	52.9M
Liabilities And Stockholders Equity	516.9M	719.6M	534.8M	386.4M	243.6M	370.4M
Non Current Liabilities Total	8.1M	42.8M	49.1M	45.9M	38.2M	37.7M
Capital Surpluse	685.0M	997.3M	1.1B	1.2B	1.4B	1.5B
Other Current Assets	4.0M	20.5M	47.6M	29.1M	9.1M	15.7M
Other Stockholder Equity	685.0M	997.3M	1.1B	1.2B	1.3B	738.6M
Total Liab	21.2M	65.2M	89.3M	76.0M	74.8M	72.9M
Property Plant And Equipment Gross	8.4M	48.1M	74.8M	69.4M	71.9M	38.8M
Total Current Assets	499.9M	669.3M	451.6M	308.8M	179.9M	328.7M
Accumulated Other Comprehensive Income	137K	8K	(153K)	(284K)	50K	52.5K
Non Current Liabilities Other	8.1M	42.8M	49.1M	45.9M	52.8M	55.5M
Short Term Debt	410K	492K	2.3M	3.2M	3.3M	2.3M
Common Stock	48K	53K	54K	85K	88K	51.6K
Property Plant Equipment	14.2M	8.3M	43.1M	39.1M	45.0M	47.3M
Net Invested Capital	495.7M	654.4M	445.5M	310.4M	168.8M	160.4M
Net Working Capital	486.8M	646.8M	411.3M	278.8M	143.3M	136.1M
Current Deferred Revenue	6.6M	7.9M	19.4M	(1.8M)	(2.0M)	(1.9M)
Retained Earnings Total Equity	(189.5M)	(343.0M)	(612.8M)	(932.8M)	(839.5M)	(797.5M)
Short Term Investments	457.5M	451.8M	271.4M	192.6M	104.4M	99.1M
Capital Lease Obligations	410K	43.3M	51.4M	49.1M	41.5M	34.1M
Capital Stock	48K	53K	54K	85K	88K	67.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Allakos is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Allakos Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Allakos Stock. Highlighted below are key reports to facilitate an investment decision about Allakos Stock:

How To Invest In Allakos

Details

Is Allakos Stock a good investment?

Details

What is Allakos' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allakos. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Allakos Stock please use our How to buy in Allakos Stock guide.

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allakos. If investors know Allakos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allakos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.03)

Return On Assets

(0.49)

Return On Equity

(1.22)

The market value of Allakos is measured differently than its book value, which is the value of Allakos that is recorded on the company's balance sheet. Investors also form their own opinion of Allakos' value that differs from its market value or its book value, called intrinsic value, which is Allakos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allakos' market value can be influenced by many factors that don't directly affect Allakos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Allakos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allakos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allakos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Allakos Research Development vs Total Operating Expenses Analysis

Research Development vs Total Operating Expenses

Research Development vs Total Operating Expenses Correlation Analysis

Correlation Coefficient

Research Development

Total Operating Expenses

Allakos fundamental ratios Correlations

Allakos Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Allakos fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net

Other Assets	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab
Capital Surpluse	- 0.95	Retained Earnings
Common Stock Total Equity	- 0.95	Retained Earnings
Cash	- 0.94	Net Debt
Common Stock Shares Outstanding	- 0.89	Retained Earnings